Fully Underwritten Entitlement Offer to Raise $32 Million
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Eligible shareholders will have the opportunity to purchase new shares at a discounted price on a pro rata basis, with the offer expected to extend the company's cash runway into the future. The funds raised will be utilized for advancing clinical studies and developing new oncology assets based on Starpharma's dendrimer technology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Starpharma Holdings Limited on 6ix
Earlier from Starpharma
- Quarterly Activities Report and Appendix 4C
- DEP milestone triggers partner option fee
- Positive DEP HER2-Lu preclinical data support Phase 1 entry
- DEP radiopharmaceutical data supports patent application
- FDA confirms path to DEP HER2 first-in-human study
Later from Starpharma
- Entitlement Offer Investor Presentation
- Successful Completion of $32 million Entitlement Offer
- Preliminary Final Report
- FY26 Key Financial Results and Annual Report
- S&P DJI Announces September 2026 Quarterly Rebalance
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma